News

Researchers showed that an mRNA influenza vaccine delivered with their new lipid nanoparticle could generate the same immune response as mRNA delivered by nanoparticles made with FDA-approved materials, but at around 1/100 the dose.

Monash University researchers used CRISPR or a PTPN2 inhibitor to enhance CAR T cell function against solid tumors. Blocking PTPN2 improved T cell persistence and tumor killing in preclinical models, creating long-lived, stem-like CAR T cells.

A nationwide study in Scotland confirms that HPV vaccination provides strong, lasting protection against cervical precancer for more than a decade. Women vaccinated at ages 12–13 showed up to 82% reduced risk of high-grade lesions.

A research team from Trinity has unveiled a groundbreaking new approach to vaccination that could redefine how we protect against respiratory infections.

Researchers genetically engineered stomach organoids to transform them into pancreatic beta cells capable of secreting insulin.

Scientists have used their discovery of previously unknown mechanisms in an anti-inflammatory pathway to develop a powerful upgrade: an engineered antibody that delivers the effectiveness of IVIG at fraction of the dose in mice.

Researchers reported encouraging results from an early phase clinical trial that found an experimental intranasal vaccine triggered a broad immune response against multiple strains of H5N1 “bird flu”.

Researchers showed that a protein language model could design functional human antibodies that recognized unique antigen sequences of specific viruses, without requiring part of the antibody sequence as a starting template.

A specific subtype of tumor-associated macrophage is more abundant in endocrine therapy-resistant tumors, and targeting these could improve treatment.

Using these antigens, researchers plan to develop vaccine candidates that they hope would stimulate a strong immune response against the world’s deadliest pathogen.